#BEGIN_DRUGCARD DB02353

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C12H16NO16S2

# Chemical_IUPAC_Name:
(2R,3R,4R)-2-{[(2S,3R,4S,5S,6S)-4,6-dihydroxy-2-(hydroxymethyl)-5-(sulfonatoamino)oxan-3-yl]oxy}-4-hydroxy-3-(sulfonatooxy)-3,4-dihydro-2H-pyran-6-carboxylate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Heparin Disaccharide Iii-S

# HET_ID:
H3S

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C12H19NO16S2/c14-2-5-9(7(16)6(11(19)26-5)13-30(20,21)22)28-12-8(29-31(23,24)25)3(15)1-4(27-12)10(17)18/h1,3,5-9,11-16,19H,2H2,(H,17,18)(H,20,21,22)(H,23,24,25)/p-3/t3-,5+,6+,7+,8-,9+,11+,12+/m1/s1

# InChI_Key:
InChIKey=GSYQGRODWXMUOO-XKUCOZAXSA-K

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2353

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
494.383

# Molecular_Weight_Mono:
493.991049849

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1U4M

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.3

# Predicted_LogS:
-1.2

# Predicted_Water_Solubility:
3.75e+01 g/l

# Primary_Accession_No:
DB02353

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936360

# PubChem_Substance_ID:
46504730

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01679

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@H](O)[C@@H](NS([O-])(=O)=O)[C@H](O)[C@H]1O[C@@H]1OC(=C[C@@H](O)[C@H]1OS([O-])(=O)=O)C([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:02 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CCL5

# Drug_Target_1_GenBank_ID_Gene:
M21121

# Drug_Target_1_GenBank_ID_Protein:
339421

# Drug_Target_1_GeneCard_ID:
CCL5

# Drug_Target_1_Gene_Name:
CCL5

# Drug_Target_1_Gene_Sequence:
>276 bp
ATGAAGGTCTCCGCGGCACGCCTCGCTGTCATCCTCATTGCTACTGCCCTCTGCGCTCCT
GCATCTGCCTCCCCATATTCCTCGGACACCACACCCTGCTGCTTTGCCTACATTGCCCGC
CCACTGCCCCGTGCCCACATCAAGGAGTATTTCTACACCAGTGGCAAGTGCTCCAACCCA
GCAGTCGTCTTTGTCACCCGAAAGAACCGCCAAGTGTGTGCCAACCCAGAGAAGAAATGG
GTTCGGGAGTACATCAACTCTTTGGAGATGAGCTAG

# Drug_Target_1_General_Function:
Involved in chemokine activity

# Drug_Target_1_General_References:
10213461	Nomiyama H, Fukuda S, Iio M, Tanase S, Miura R, Yoshie O: Organization of the chemokine gene cluster on human chromosome 17q11.2 containing the genes for CC chemokine MPIF-1, HCC-2, HCC-1, LEC, and RANTES. J Interferon Cytokine Res. 1999 Mar;19(3):227-34.
1380064	Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992 Aug 1;176(2):587-92.
2456327	Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM: A human T cell-specific molecule is a member of a new gene family. J Immunol. 1988 Aug 1;141(3):1018-25.
7537088	Skelton NJ, Aspiras F, Ogez J, Schall TJ: Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry. 1995 Apr 25;34(16):5329-42.
7542919	Chung CW, Cooke RM, Proudfoot AE, Wells TN: The three-dimensional solution structure of RANTES. Biochemistry. 1995 Jul 25;34(29):9307-14.
8525373	Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995 Dec 15;270(5243):1811-5.
9516414	Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J: Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem. 1998 Mar 27;273(13):7222-7.
9889151	Wilken J, Hoover D, Thompson DA, Barlow PN, McSparron H, Picard L, Wlodawer A, Lubkowski J, Kent SB: Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES. Chem Biol. 1999 Jan;6(1):43-51.

# Drug_Target_1_HGNC_ID:
HGNC:10632

# Drug_Target_1_HPRD_ID:
01751

# Drug_Target_1_ID:
1367

# Drug_Target_1_Locus:
17q11.2-q12

# Drug_Target_1_Molecular_Weight:
9990

# Drug_Target_1_Name:
Small inducible cytokine A5

# Drug_Target_1_Number_of_Residues:
91

# Drug_Target_1_PDB_ID:
1U4M

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00048	IL8

# Drug_Target_1_Protein_Sequence:
>Small inducible cytokine A5 precursor
MKVSAAALAVILIATALCAPASASPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNP
AVVFVTRKNRQVCANPEKKWVREYINSLEMS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-23

# Drug_Target_1_Specific_Function:
Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. Binds to CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T- cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils

# Drug_Target_1_SwissProt_ID:
P13501

# Drug_Target_1_SwissProt_Name:
CCL5_HUMAN

# Drug_Target_1_Synonyms:
CCL5
SIS-delta
Small inducible cytokine A5 precursor
T cell-specific protein P228
T-cell-specific RANTES protein
TCP228

# Drug_Target_1_Theoretical_pI:
9.30

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02353
